Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-30. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Schabowski gave a confusing answer that asserted it was necessary because West Germany had exhausted its capacity to accept fleeing East Germans, then remembered the note he had been given and added that a new regulation had been drafted to allow permanent emigration at any border crossing. This caused a stir in the room; amid several questions at once, Schabowski expressed surprise that the reporters had not yet seen this regulation, and started reading from the note. After this, a reporter, either Ehrman or Bild-Zeitung reporter Peter Brinkmann, both of whom were sitting in the front row at the press conference, asked when the regulations would take effect. After a few seconds' hesitation, Schabowski replied, "As far as I know, it takes effect immediately, without delay" (German: Das tritt nach meiner Kenntnis ... ist das sofort ... unverzüglich). This was an apparent assumption based on the note's opening paragraph; as Beil attempted to interject that it was up to the Council of Ministers to decide when it took effect, Schabowski proceeded to read this clause, which stated it was in effect until a law on the matter was passed by the Volkskammer. Crucially, a journalist then asked if the regulation also applied to the crossings to West Berlin. Schabowski shrugged and read item 3 of the note, which confirmed that it did. After this exchange, Daniel Johnson of The Daily Telegraph asked what this law meant for the Berlin Wall. Schabowski sat frozen before giving a rambling statement about the Wall being tied to the larger disarmament question.
The court's decision protects active service members from being dismissed, but doesn't abolish the ban on recruitment. June 2 The U.S. Supreme Court allows Alabama to redistrict its congressional map for the upcoming midterm elections. The new map favors the Republican Party. Trump names businessman Bill Pulte as the acting Director of National Intelligence, replacing Tulsi Gubbard who resigned. The New York Times reports that the DOJ is investigating former U.S. Representative George Santos for insider trading on Kalshi by betting on himself that he would not show up to the 2026 State of the Union Address. The Trump administration proposes a 10% tariff on countries who failed to enforce bans on products made with forced labor. Trump suggests that the UFC Arena being built on the White House's South Lawn for the June 14th UFC Freedom 250 fights could be a permanent installation, likening it to France's decision to keep the Eiffel Tower after the 1889 Paris Exposition. June 3 The U.S. House passes a resolution by a vote of 215–208 to limit Trump's war powers and end hostilities in the Iran war with four Republicans (Tom Barrett (MI), Warren Davidson (OH), Brian Fitzpatrick (PA), and Thomas Massie (KY)) joining all Democrats. The resolution is seen as symbolic as it would need to pass the U.S. Senate and survive a presidential veto; Trump derides the defecting Republicans as "grandstanders". Senate Republicans strip $1 billion in funding for security upgrades to the proposed White House ballroom from a revised budget reconciliation bill.
=== Erroneous and incomplete discoveries === In 1914, Stefan Meyer, Viktor F. Hess, and Friedrich Paneth (working in Vienna) made measurements of alpha radiation from various substances, including 227Ac. They observed the possibility of a minor alpha branch of this nuclide, though follow-up work could not be done due to the outbreak of World War I. Their observations were not precise and sure enough for them to announce the discovery of element 87, though it is likely that they did indeed observe the decay of 227Ac to 223Fr. Soviet chemist Dmitry Dobroserdov was the first scientist to claim to have found eka-caesium, or francium. In 1925, he observed weak radioactivity in a sample of potassium, another alkali metal, and incorrectly concluded that eka-caesium was contaminating the sample (the radioactivity from the sample was from the naturally occurring potassium radioisotope, potassium-40). He then published a thesis on his predictions of the properties of eka-caesium, in which he named the element russium after his home country. Shortly thereafter, Dobroserdov began to focus on his teaching career at the Polytechnic Institute of Odesa, and he did not pursue the element further. The following year, English chemists Gerald J. F. Druce and Frederick H. Loring analyzed X-ray photographs of manganese(II) sulfate. They observed spectral lines which they presumed to be of eka-caesium. They announced their discovery of element 87 and proposed the name alkalinium, as it would be the heaviest alkali metal.
==== Escaping to Wales ==== The Thomas family also made several escapes back to Wales. Between 1941 and 1943, they lived intermittently in Plas Gelli, Talsarn, in Cardiganshire. Plas Gelli sits close by the River Aeron, after whom Aeronwy is thought to have been named. Some of Thomas's letters from Gelli can be found in his Collected Letters whilst an extended account of Thomas's time there can be found in D. N. Thomas's book, Dylan Thomas: A Farm, Two Mansions and a Bungalow (2000). The Thomases shared the mansion with his childhood friends from Swansea, Vera and Evelyn Phillips. Vera's friendship with the Thomases in nearby New Quay is portrayed in the 2008 film The Edge of Love. In July 1944, with the threat in London of German flying bombs, Thomas moved to the family cottage at Blaencwm near Llangain, Carmarthenshire, where he resumed writing poetry, completing Holy Spring and Vision and Prayer. In September that year, the Thomas family moved to New Quay in Cardiganshire (Ceredigion), where they rented Majoda, a wood and asbestos bungalow on the cliffs overlooking Cardigan Bay. It was there that Thomas wrote a radio piece about New Quay, Quite Early One Morning, a sketch for his later work, Under Milk Wood.
== Bibliography == Brock, Sebastian P. (1987). "North Mesopotamia in the late Seventh Century: Book XV of John Bar Penkāyē's Rīš Mellē". Jerusalem Studies in Arabic and Islam. 9: 51–75. ISSN 0334-4118. Crone, Patricia (1980). Slaves on Horses: The Evolution of the Islamic Polity (1980 ed.). Cambridge: Cambridge University Press. p. 93. ISBN 978-0521229616. Donner, Fred M. (2010). Muhammad and the Believers. Cambridge: The Belknap Press of Harvard University Press. ISBN 978-0-674-05097-6. Gibb, H. A. R. (2013) [1923]. The Arab Conquests in Central Asia. Read Books. ISBN 1-4067-5239-8. Gibb, H. A. R. (2007). The Arab Conquests in Central Asia. Read Books. ISBN 978-1-4067-5239-7. reprinted from the 1923 edition, published by the Royal Asiatic Society OCLC 474026895. Hasson, I. (2002). "Ziyād b. Abiḥī". In Bearman, P. J.; Bianquis, Th.; Bosworth, C. E.; van Donzel, E.; Heinrichs, W. P. (eds.). The Encyclopedia of Islam. Vol. XI: W–Z (new ed.). Leiden and New York: Brill. pp. 519–522. ISBN 90-04-12756-9. Kennedy, Hugh (2001). The Armies of the Caliphs: Military and Society in the Early Islamic State. London and New York: Routledge. ISBN 0-415-25093-5. Kennedy, Hugh (2004) [1986]. The Prophet and the Age of the Caliphates: The Islamic Near East from the 6th to the 11th Century (Second ed.). Harlow: Longman. ISBN 978-0-582-40525-7. Madelung, Wifred (October 1981). "ʿAbd Allāh b. al-Zubayr and the Mahdi". Journal of Near Eastern Studies. 4 (1): 291–305. ISSN 0022-2968. JSTOR 544603. Robinson, C. F. (2000). "ʿUbayd Allāh b. Ziyād". In Bearman, P. J.; Bianquis, Th.; Bosworth, C.
Sources: en.wikipedia.org
==== Steatosis ==== Hepatotoxicity may manifest as triglyceride accumulation, which leads to either small-droplet (microvesicular) or large-droplet (macrovesicular) fatty liver. There is a separate type of steatosis by which phospholipid accumulation leads to a pattern similar to the diseases with inherited phospholipid metabolism defects (e.g., Tay–Sachs disease)
The United 2026 bid beat a rival bid by Morocco during a final vote at the 68th FIFA Congress in Moscow in 2018. The previous year, FIFA president Gianni Infantino had stated that Europe (UEFA confederation) and Asia (AFC) would be excluded from the bidding following the selection of Russia for the 2018 World Cup and Qatar for the 2022 tournament. Therefore, the 2026 World Cup could be hosted by one of the remaining four confederations: CONCACAF (North America; last hosted in 1994), CAF (Africa; last hosted in 2010), CONMEBOL (South America; last hosted in 2014), or OFC (Oceania, never hosted), or potentially by AFC or UEFA in case no bid from the others met FIFA's requirements. Co-hosting of the World Cup—which had been suspended by FIFA after the 2002 edition—was approved for the enlarged 2026 tournament. Canada, Mexico, and the United States had each considered bidding for the tournament separately; the United joint bid was announced on April 10, 2017. The Moroccan bid was announced that August.
Alfred Otto Carl Nier (May 28, 1911 – May 16, 1994) was an American physicist who pioneered the development of mass spectrometry. He was the first to use mass spectrometry to isolate uranium-235 which was used to demonstrate that 235U could undergo fission and developed the sector mass spectrometer configuration now known as Nier-Johnson geometry.
=== High blood pressure === Valsartan and hydrochlorothiazide are both medications indicated as initial therapy for high blood pressure. When high blood pressure is not effectively controlled on a single medication they can be used in a combination.
Sources: en.wikipedia.org
Many of the characteristics of micelles differ from those of bulk solvents. For example, the micelles are, by nature, spatially heterogeneous with a hydrocarbon, nearly anhydrous core and a highly solvated, polar head group. They have a high surface-to-volume ratio due to their small size and generally spherical shape. Their surrounding environment (pH, ionic strength, buffer ion, presence of a co-solvent, and temperature) has an influence on their size, shape, critical micelle concentration, aggregation number and other properties. Another important property of micelles is the Krafft point, the temperature at which the solubility of the surfactant is equal to its CMC. For HPLC applications involving micelles, it is best to choose a surfactant with a low Krafft point and CMC. A high CMC would require a high concentration of surfactant which would increase the viscosity of the mobile phase, an undesirable condition. Additionally, a Krafft point should be well below room temperature to avoid having to apply heat to the mobile phase. To avoid potential interference with absorption detectors, a surfactant should also have a small molar absorptivity at the chosen wavelength of analysis. Light scattering should not be a concern due to the small size, a few nanometers, of the micelle. The effect of organic additives on micellar properties is another important consideration. A small amount of organic solvent is often added to the mobile phase to help improve efficiency and to improve separations of compounds. Care needs to be taken when determining how much organic to add.
==== Computer tomography ==== In 1972, the first commercial CT scanner for clinical use went into operation at Atkinsons Morley Hospital in London. Its inventor was the English engineer Godfrey Newbold Hounsfield (1919-2004), who shared the 1979 Nobel Prize in Medicine with Allan McLeod Cormack (1924-1998) for his pioneering work in the field of computed tomography. The first steps toward dose reduction were taken in 1989 in the era of single-slice spiral CT. The introduction of multi-slice spiral computed tomography in 1998 and its continuous development made it possible to reduce the dose by means of dose modulation. The tube current is adjusted, for example by reducing the power for images of the lungs compared to the abdomen. The tube current is modulated during rotation. Because the human body has an approximately oval cross-section, radiation intensity is reduced when radiation is delivered from the front or back, and is increased when radiation is delivered from the side. This dose control also depends on the body mass index. For example, the use of dose modulation in the head and neck region reduces total exposure and organ doses to the thyroid and eye lens by up to 50% without significantly compromising diagnostic image quality. The Computed Tomography Dose Index (CTDI) is used to measure radiation exposure during a CT scan. The CTDI was first defined by the Food and Drug Administration (FDA) in 1981. The unit of measurement for the CTDI is the mGy (milli-Gray).
Compton had recently founded the American Research and Development Corporation (ARD) to spur the formation of new post-war industries. He introduced the founders to ARD's president, Georges Doriot. Doriot predicted the cancer treatment machines would be a commercial failure. Nevertheless, he perceived HVEC's leaders to be technically capable, and Compton persuaded him that ARD should have a startup with clear human benefits. Among more than 400 applications, Doriot selected the firm among ARD's first three investments. He offered the founders $200,000 in initial capitalization, leaving half the equity to them and their staff consultants. Compton arranged for HVEC to exclusively license MIT's Van de Graaff and Trump patents. Both Compton and Doriot served on the new company's board.
Barcoding is a common and cost-effective method used to implement traceability at both the item and case-level. Variable data in a barcode or a numeric or alphanumeric code format can be applied to the packaging or label. The secure data can be used as a pointer to traceability information and can also correlate with production data such as time to market and product quality. Packaging converters have a choice of three different classes of technology to print barcodes:
==== Season 4 ==== Months later, Logan remains estranged from his children. On the eve of the GoJo acquisition, Sandi and Stewy convince the siblings to delay the board vote to increase the price of the sale, forcing Logan to attempt reconciliation with his children. Kendall and Shiv refuse to budge, unsuccessfully demanding an apology from their father for his betrayal and his cruel parenting. Logan is then left no choice but to go to Sweden to renegotiate the deal with Matsson, but he suddenly dies on the flight from a pulmonary embolism, with only Tom and some of his other senior team by his side. Tom phones the children - who are attending Connor's wedding - to give them a chance to say goodbye. The plane is turned around and Logan is pronounced dead on arrival; the siblings make a statement announcing his death to the press, then watch as his body is removed from the plane. During Logan's wake, an undated document is found in his safe naming Kendall his successor upon his death, with several pencil addenda included, including a strike on "Kendall Roy" that could be either underlining or crossing-out the name. Kendall and Roman eventually decide to run the company together as co-CEOs, since the company's succession plan formally dictated leadership be passed down to COO - Roman's role at the time.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.